BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 22724067)

  • 21. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis.
    Donnenberg VS; Donnenberg AD
    J Clin Pharmacol; 2005 Aug; 45(8):872-7. PubMed ID: 16027397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
    Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z
    Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs.
    Aszalos A; Ross DD
    Anticancer Res; 1998; 18(4C):2937-44. PubMed ID: 9713488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells.
    Martín V; Sanchez-Sanchez AM; Herrera F; Gomez-Manzano C; Fueyo J; Alvarez-Vega MA; Antolín I; Rodriguez C
    Br J Cancer; 2013 May; 108(10):2005-12. PubMed ID: 23632480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of ABCG2 and p-glycoprotein in residual breast cancer tissue after chemotherapy and their correlation with epithelial-mesenchymal transition].
    Qu H; Fang L; Duan L; Long X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):236-40. PubMed ID: 24915813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures.
    Chen J; Wang J; Chen D; Yang J; Yang C; Zhang Y; Zhang H; Dou J
    BMC Cell Biol; 2013 Jan; 14():7. PubMed ID: 23368632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unanswered questions about multidrug resistance.
    Beck WT
    Cytotechnology; 1996; 19(3):177-9. PubMed ID: 8862003
    [No Abstract]   [Full Text] [Related]  

  • 30. Colon cancer: cancer stem cells markers, drug resistance and treatment.
    Kozovska Z; Gabrisova V; Kucerova L
    Biomed Pharmacother; 2014 Oct; 68(8):911-6. PubMed ID: 25458789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
    Pérez-Tomás R
    Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug resistance: still a daunting challenge to the successful treatment of AML.
    Shaffer BC; Gillet JP; Patel C; Baer MR; Bates SE; Gottesman MM
    Drug Resist Updat; 2012; 15(1-2):62-9. PubMed ID: 22409994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABCG2: the key to chemoresistance in cancer stem cells?
    An Y; Ongkeko WM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1529-42. PubMed ID: 19708828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade.
    Loebinger MR; Giangreco A; Groot KR; Prichard L; Allen K; Simpson C; Bazley L; Navani N; Tibrewal S; Davies D; Janes SM
    Br J Cancer; 2008 Jan; 98(2):380-7. PubMed ID: 18219291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.
    Sui H; Zhu L; Deng W; Li Q
    Oncol Res Treat; 2014; 37(10):584-9. PubMed ID: 25342509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.
    Boesch M; Zeimet AG; Rumpold H; Gastl G; Sopper S; Wolf D
    Stem Cells Transl Med; 2015 Sep; 4(9):1028-32. PubMed ID: 26136502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
    Wang F; Mi YJ; Chen XG; Wu XP; Liu Z; Chen SP; Liang YJ; Cheng C; To KK; Fu LW
    Mol Med; 2012 Jul; 18(1):887-98. PubMed ID: 22549112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.
    Blagosklonny MV
    Leukemia; 2001 Jun; 15(6):936-41. PubMed ID: 11417480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fundamental bases of combined therapy in lung cancer: cell resistance to chemotherapy and radiotherapy.
    Duchesne GM
    Lung Cancer; 1994 Mar; 10 Suppl 1():S67-72. PubMed ID: 7916253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.